Loading...
Partnering2019-04-12T15:57:58+01:00

Overview

We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed research collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and we seek additional partnerships.

We also have an extensive pipeline of partnered NCEs in pre-clinical and clinical development with Corvus, Celgene, CTI BioPharma, Servier and Verona Pharma, and we explore additional licensing opportunities for our currently unpartnered drug candidates.

To find out more about partnering with us, please contact us.

Research collaborations

We are involved in a number of research collaborations with major pharmaceutical companies and academic partners. These range from early stage research, establishing target tractability, through to late-stage lead optimisation programs. We value close cooperation with our collaborators to ensure that the combined strengths of the partners are most effectively deployed to deliver drug candidates. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success.

Current disclosed collaborations include those with:

Servier: two development stage collaborations on the Bcl-2 family of proteins and four further research collaborations on undisclosed oncology targets.

Daiichi Sankyo: a research collaboration on undisclosed oncology targets.

Lundbeck: a research collaboration targeting LRRK2 for the treatment of Parkinson’s disease.

Asahi Kasei Pharma: a research collaboration targeting rheumatoid arthritis.

For further information about collaboration opportunities, or to get more information about Vernalis Research capabilities, please feel free to contact us.

NCE pipeline

We have an extensive portfolio of new chemical entities (NCEs) in pre-clinical and clinical development. Our broad and maturing pipeline of drug candidates covers a range of therapeutic areas, and has a healthy mix of partnered and unpartnered programmes.

Partnered

Unpartnered

Therapeutic areaCandidateDevelopment stageRights
CNSV158866
Phase II
Vernalis
Immuno-oncologyCPI-444
Phase II
Corvus Pharmaceuticals
Immuno-oncologyVipadenant
Pre-clinical
RedoxTherapies (a Celgene company)
OncologyLuminespib
Phase II
Vernalis
OncologyTosedostat
Phase II
CTI BioPharma
OncologyS55746
Phase I
Servier in collaboration with Novartis
OncologyS64315
Phase I
Servier in collaboration with Novartis
OncologyV158411
Pre-clinical
Vernalis
InflammationRPL554
Phase II
Verona Pharma
This website uses cookies and third party services. Read our Privacy Policy Ok